Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

1.14AUD
8:33pm EDT
Change (% chg)

$0.01 (+0.88%)
Prev Close
$1.13
Open
$1.14
Day's High
$1.15
Day's Low
$1.13
Volume
30,657
Avg. Vol
1,146,991
52-wk High
$4.05
52-wk Low
$1.01

MSB.AX

Chart for MSB.AX

About

Mesoblast Limited is engaged in the development of adult stem cell technology platform for commercialization. The Company develops a portfolio of regenerative therapeutic cell-based products. Its portfolio of therapeutic products is being developed using its technology platforms, which include specialized cells known as... (more)

Overall

Beta: 1.27
Market Cap(Mil.): $432.86
Shares Outstanding(Mil.): 381.37
Dividend: --
Yield (%): --

Financials

  MSB.AX Industry Sector
P/E (TTM): -- 39.80 37.05
EPS (TTM): -0.32 -- --
ROI: -- -5.86 14.35
ROE: -- -4.70 15.56

BRIEF-Mesoblast provides update on heart failure trial and funding of clinical operations

* Mesoblast provides update on heart failure trial and funding of clinical operations Source text for Eikon: Further company coverage: )

Jul 01 2016

UPDATE 1-Mesoblast shares slump to 2009 low as Teva ends partnership

* Mesoblast shares plummet 42 pct to lows not seen since 2009

Jun 14 2016

Australia, NZ shares slump on Fed, Brexit worries

MELBOURNE/WELLINGTON, June 14 Australian shares dropped 2 percent on Tuesday to a one-month low while New Zealand fell for a second day tracking declines offshore on worries about U.S. growth and Britain potentially pulling out of the European Union.

Jun 14 2016

Mesoblast regains full rights to stem cell heart failure treatment

Mesoblast Ltd on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure, which is currently in late stage testing, from Teva Pharmaceutical Industries.

Jun 13 2016

Mesoblast regains full rights to stem cell heart failure treatment

Mesoblast Ltd on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure, which is currently in late stage testing, from Teva Pharmaceutical Industries.

Jun 13 2016

Mesoblast regains full rights to stem cell heart failure treatment

June 13 Mesoblast Ltd on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure, which is currently in late stage testing, from Teva Pharmaceutical Industries.

Jun 13 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.